加载中
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
前收盘价
US$196.48
+US$9.02 · +4.81%
盘后
US$195.89
−US$0.59 · -0.30%
10月7日 19:59 ET
盘中时间采用ET。市场数据可能有所延迟。
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
日内区间
当前US$196.48
52周区间
当前US$196.48
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
24
偏贵
情绪
50
多空交织
风险
46
风险偏高
动量
82
强势上行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
日内区间
当前US$196.48
52周区间
当前US$196.48
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 19.44亿 USD | 31.99亿 USD | 68.48亿 USD | 188.75亿 USD | 177.36亿 USD |
| 销货成本 | 8.68亿 USD | 14.64亿 USD | 46.93亿 USD | 54.16亿 USD | 26.17亿 USD |
| 毛利 | 10.76亿 USD | 17.35亿 USD | 21.55亿 USD | 134.59亿 USD | 151.19亿 USD |
| 研究与开发 | 31.32亿 USD | 45.43亿 USD | 48.45亿 USD | 32.95亿 USD | 19.91亿 USD |
| 销售、一般及管理费用 | 10.18亿 USD | 11.74亿 USD | 15.49亿 USD | 11.32亿 USD | 5.67亿 USD |
| 营业费用 | 41.5亿 USD | 56.8亿 USD | 63.94亿 USD | 40.39亿 USD | 18.23亿 USD |
| 利息收入 | 3.14亿 USD | 4.25亿 USD | 4.21亿 USD | 2亿 USD | 1800万 USD |
| 利息支出 | 1000万 USD | 2400万 USD | 3800万 USD | 2900万 USD | 1800万 USD |
| 折旧和摊销 | 2.15亿 USD | 1.89亿 USD | 6.21亿 USD | 3.48亿 USD | 2.32亿 USD |
| 营业利润 | −30.74亿 USD | −39.45亿 USD | −42.39亿 USD | 94.2亿 USD | 132.96亿 USD |
| 净利润 | −28.22亿 USD | −35.61亿 USD | −47.14亿 USD | 83.62亿 USD | 122.02亿 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
SPDR S&P 500 ETF Trust1557.T1338.38亿0.10%129.38万亿 JPY0.09%JP¥122,900-0.41%
Vanguard Morningstar Total Stock Market ETFVTI15.93亿0.07%2.3万亿 USD0.03%US$381.03-0.40%
Vanguard S&P 500 ETFVOO13.17亿0.07%1.8万亿 USD0.03%US$714.34-0.26%
Vanguard Morningstar Small-Cap ETFVB11.53亿0.62%1853亿 USD0.03%US$286.98-1.41%
iShares Core S&P 500 ETFIVV9.27亿0.10%8996.25亿 USD0.03%US$780.58-0.25%
State Street SPDR S&P 500 ETFSPY8.45亿0.10%8184.58亿 USD0.09%US$777.22-0.24%
Vanguard Morningstar Small-Cap Value ETFVBR7.32亿1.07%682亿 USD0.05%US$232.17-1.32%
iShares Biotechnology ETFIBB5.18亿4.98%104.01亿 USD0.44%US$203.34+0.12%SPDR S&P 500 ETF Trust1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYVanguard Morningstar Small-Cap Value ETFVBRiShares Biotechnology ETFIBBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
